Surrozen, Inc. (NASDAQ:SRZN) CFO Charles O. Williams Sells 1,181 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) CFO Charles O. Williams sold 1,181 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $17.37, for a total value of $20,513.97. Following the sale, the chief financial officer now directly owns 8,982 shares of the company’s stock, valued at approximately $156,017.34. This represents a 11.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Surrozen Price Performance

Shares of SRZN opened at $14.23 on Tuesday. Surrozen, Inc. has a 1 year low of $6.00 and a 1 year high of $18.17. The company’s fifty day moving average is $10.92 and its two-hundred day moving average is $9.90.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The firm had revenue of $10.00 million for the quarter. On average, sell-side analysts predict that Surrozen, Inc. will post -7.16 earnings per share for the current year.

Hedge Funds Weigh In On Surrozen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new stake in shares of Surrozen in the 2nd quarter valued at approximately $2,080,000. Nantahala Capital Management LLC purchased a new position in Surrozen in the second quarter worth $2,050,000. Stonepine Capital Management LLC acquired a new stake in Surrozen in the second quarter valued at $724,000. Finally, CVI Holdings LLC purchased a new stake in shares of Surrozen during the 2nd quarter worth $711,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Analysts Set New Price Targets

Separately, Guggenheim raised Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.